R.G. GAMIROVA^1, 2, R.M. SHAIMARDANOVA³, R.R. GAMIROVA², V.F. PRUSAKOV¹

 ¹Kazan State Medical Academy — Branch Campus of RMACPE MH Russia, Kazan

²Kazan Federal University,  Kazan

³Сhildren’s Сity Hospital № 8,  Kazan

 Contact details:

Gamirova R.G. — Ph. D. (medicine), Associate Professor of the Pediatric Neurology Department, Associate Professor of the Department of Fundamentals of Clinical Medicine, Senior Researcher of the Laboratory of Clinical Linguistics

Address: 11 Mushtari St., Kazan, Russian Federation, 420012, tel.: + 7-917-257-96-44, e-mail: r-gamirov@mail.ru

 The purpose — to analyze relevant information about the etiology, prevalence, clinical features, and the comparative effectiveness of antiepileptic drugs in the treatment of patients with juvenile myoclonic epilepsy (JME).

Material and methods. We analyzed publications in the available medical databases PubMed, Cochrane Library for the period 1980–2019 concerning epidemiology, pathogenesis, clinics and treatment effectiveness of JME.

Results. According to the studies, which had predominantly retrospective observational design, valproate monotherapy had shown a better therapeutic effect in JME versus lamotrigine, topiramate, levetiracetam, and carbamazepine. The use of valproic acid in JME is increasingly limited due to its undesirable drug reactions, teratogenicity, and neurotoxicity.

Conclusion. At present, problems with the management tactics of patients with JME persist, there is a lack of methodologically correctly conducted randomized clinical trials regarding the comparative effectiveness of antiepileptic drugs in this disease.

Key words: juvenile myoclonic epilepsy, idiopathic generalized epilepsy, treatment of epilepsy, side effects of antiepileptic drugs.

 (For citation: Gamirova R.G., Shaimardanova R.M., Gamirova R.R., V.F. Prusakov V.F. New view at clinical and therapeutic aspects of juvenile myoclonic epilepsy. Practical Medicine. 2019. Vol. 17, № 7, P. 33-37)

REFERENCES

1. Genton P. et al. Clinical aspects of juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, vol. 28, rr. S8-S14. doi: 10.1016/j.yebeh.2012.10.034
2. Fisher R.S. et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017, vol. 58 (4), pp. 522–530. doi: 10.1111/epi.13670
3. Janz D., Christian W. Impulsiv-petit mal. Journal of neurology, 1957, vol. 176 (3), pp. 346–386.
4. Janz D. Epilepsy with impulsive petit mal (juvenile myoclonic epilepsy). Acta Neurologica Scandinavica, 1985, vol. 72 (5), pp. 449–459. doi: 10.1111/j.1600-0404.1985.tb00900.x
5. Delgado-Escueta A.V., Enrile-Bacsal F.E. Juvenile myoclonic epilepsy of Janz. Neurology, 1984, vol. 34 (3), pp. 285–285. doi: 10.1212/WNL.34.3.285
6. Online Mendelian Inheritance in Man (OMIM®). 1966–2019 Johns Hopkins University, available at: https://omim.org/
7. Afavi Z. et al. Modern advances in the field of genetic research of idiopathic generalized epilepsies. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. Spetsvypuski, 2018, vol. 118, no. 10, pp. 56–60 (in Russ.). doi: 10.17116/jnevro201811810256
8. Camfield C.S., Striano P., Camfield P.R. Epidemiology of juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, vol. 28, pp. S15–S17. doi: 10.1016/j.yebeh.2012.06.024
9. Nicolson A. et al. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. Journal of Neurology, Neurosurgery & Psychiatry, 2004, vol. 75 (1), pp. 75–79.
10. Wang L. et al. Electroclinical aspects and therapy of Han patients with juvenile myoclonic epilepsy in northern China. Epilepsy & Behavior, 2016, vol. 62, pp. 204–208. doi: 10.1016/j.yebeh.2016.07.011
11. Pedersen S.B., Petersen K.A. Juvenile myoclonic epilepsy: clinical and EEG features. Acta Neurologica Scandinavica, 1998, vol. 97 (3), pp. 160–163. doi: 10.1111/j.1600-0404.1998.tb00630.x
12. Resor Jr S.R., Resor L.D. The neuropharmacology of juvenile myoclonic epilepsy. Clinical neuropharmacology, 1990, vol. 13 (6), pp. 465–491. doi: 10.1097/00002826-199012000-00001
13. da Silva Sousa P. et al. Self-perception of factors that precipitate or inhibit seizures in juvenile myoclonic epilepsy. Seizure, 2005, vol. 14 (5), pp. 340–346. doi: 10.1016/j.seizure.2005.04.007
14. Martínez-Juárez I.E. et al. Juvenile myoclonic epilepsy subsyndromes: family studies and long-term follow-up. Brain, 2006, vol. 129 (5), pp. 1269–1280. doi: 10.1093/brain/awl048
15. Chowdhury A., Brodie M.J. Pharmacological outcomes in juvenile myoclonic epilepsy: support for sodium valproate. Epilepsy research, 2016, vol. 119, pp. 62–66. doi: 10.1016/j.eplepsyres.2015.11.012
16. Trenité D.G.A.K.N. et al. Consensus on diagnosis and management of JME: from founder’s observations to current trends. Epilepsy & Behavior, 2013, vol. 28, pp. S87–S90. doi: 10.1016/j.yebeh.2012.11.051
17. Gamirova R., Abakumova T., Ziganshina L.E. Gabapentin monotherapy for epilepsy. The Cochrane database of systematic reviews, 2017, vol. 2017 (6). doi:10.1002/14651858.cd012710
18. Landmark C.J. et al. Long-term follow-up with therapeutic drug monitoring of antiepileptic drugs in patients with juvenile myoclonic epilepsy. Epilepsy research, 2019, vol. 155, rr. 106–148. DOI:10.1016/j.eplepsyres.2019.05.016
19. Jayalakshmi S. et al. Factors associated with lack of response to valproic acid monotherapy in juvenile myoclonic epilepsy. Seizure, 2014, vol. 23 (7), pp. 527–532. doi: 10.1016/j.seizure.2014.03.017
20. Marson A.G. et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblended randomised controlled trial. The Lancet, 2007, vol. 369, pp. 1016–1026. doi: 10.1016/S0140-6736(07)60461-9
21. Kinney M.O., Craig J.J. Pregnancy and epilepsy; meeting the challenges over the last 25 years: The rise of the pregnancy registries. Seizure, 2017, vol. 44, pp. 162–168. doi:10.1016/j.seizure.2016.10.004
22. Nanau R.M., Neuman M.G. Adverse drug reactions induced by valproic acid. Clinical biochemistry, 2013, vol. 46 (15), pp. 1323–1338. doi: 10.1016/j.clinbiochem.2013.06.012
23. Tomson T. et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. The Lancet Neurology, 2018, vol. 17 (6), pp. 530–538. doi: 10.1016/S1474-4422(18)30107-8
24. Silvennoinen K. et al. Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia Open, 2019. doi: 10.1002/epi4.12349
25. Crespel A. et al. Management of juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, vol. 28, pp. S81–S86. doi: 10.1016/j.yebeh.2013.01.001
26. Senf P. et al. Prognosis of juvenile myoclonic epilepsy 45 years after onset: seizure outcome and predictors. Neurology, 2013, vol. 81 (24), pp. 2128–2133. doi: 10.1212/01.wnl.0000437303.36064.f8
27. Mole T.B., Appleton R., Marson A. Withholding the choice of sodium valproate to young women with generalised epilepsy: Are we causing more harm than good? Seizure, 2015, vol. 24, pp. 127–130. doi: 10.1016/j.seizure.2014.08.006
28. Asadi-Pooya A.A., Hashemzehi Z., Emami M. Predictors of seizure control in patients with juvenile myoclonic epilepsy (JME). Seizure, 2014, vol. 23 (10), pp. 889–891. doi: 10.1016/j.seizure.2014.08.004
29. Gamirova R.G., Shaymardanova R.M. Lafora disease is a difficult patient in the work of a neurologist. Rossiyskiy vestnik perinatologii i pediatrii, 2018, vol. 63, no. 5, pp. 177–183 (in Russ.). doi:10.21508/1027-4065-2018-63-5-177-182
30. Shaimardanova R., Gamirova R., Zaikova F. Pharmacoepidemiological assessment of the medicines for juvenile idiopathic generalized epilepsies. Epilepsia, 2015, vol. 56, pp. 56–57.